Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

Inclusion criteria

• Between 18 and 65 years of age.
• Healthy.
• Subject is a nonsmoker.
• Subject's body mass index (BMI) is >=18 kilogram/meter square (kg/m^2) and <=30 kg/m^2
• Male or
• Female

Exclusion criteria

• Alanine aminotransferase (ALT) >1.5 x upper limit of normal range (ULN)
• Bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent [%]).
• Current or chronic history of liver disease, or known hepatic or biliary abnormalities
• QT interval corrected for heart rate according to Fridericia's formula (QTcF) > 450 millisecond (msec).
• Systolic blood pressure is >=140 millimeter of mercury (mmHg) at Screening;
• Diastolic blood pressure is >=90 mmHg at Screening;
• Heart rate is >100 beats/min at Screening.
• estimated glomerular filtration rate (eGFR) <=80 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2) (calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) at Screening.
• Fasting triglyceride level >300 milligram per deciliter (mg/dL) at Screening.
• History of significant cardiovascular or pulmonary dysfunction prior to Screening.
• History of thyroid dysfunction or an abnormal (i.e., outside the normal reference range) thyroid function test assessed by thyroid stimulating hormone at Screening.
• History of gastrointestinal surgery that could influence gastric emptying (e.g., gastrectomy, gastric bypass).
• History of pancreatitis.
• Personal or family history of multiple endocrine neoplasia type 2.
• Personal or family history of medullary carcinoma of the thyroid.
• Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days.
• History of regular alcohol consumption within 6 months of the study.
• Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.
• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy.
• Subject has previously received any GLP-1 mimetic compound (eg., exenatide, liraglutide, lixisenatide, dulaglutide).
• Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment.
• A positive pre-study drug/alcohol screen.
• A positive test for human immunodeficiency virus (HIV) antibody.
• Subject has donated blood in excess of 500 mL within 56 days prior to dosing or intention of donating in the month after completing the study.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day